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Background: Oral cavity squamous cell carcinoma (OCSCC) is the most common head and neck cancer, affecting
approximately 2000 Canadians yearly. Analysis of Canadian Cancer Registry data has shown that the incidence of
oral cavity cancer is decreasing and survival outcomes are improving.
There are significant health disparities in First Nations (FN) people in Canada. The incidence of cancer in FN groups
is significantly lower when compared to the general population, but the cancer-related morbidity and mortality is
significantly higher. There is no Canadian literature currently for OCSCC, or any other head and neck cancer, that
compares survival outcomes of FN to the overall population. Therefore, the objective of this study is to determine
whether there is a difference in epidemiology and survival outcomes between FN and non-FN patients with OCSCC.
Methods: This is a retrospective study of a population-based, prospectively-collected database from Alberta Cancer
Registry (ACR). Patients with OCSCC, diagnosed and treated in Alberta between 1998 and 2009 were included. ACR data
collected included patient gender, age at diagnosis, tobacco and alcohol use, FN status, TNM staging, performance
status, date of death, cause of death, and follow-up. FN status was identified through the Alberta Health and Wellness
registry and through postal code correlation for those who live on reserves.
Results: A total of 583 patients with OCSCC were included in this study. Of these, 19 were identified as being FN,
leaving 564 non-FN patients. When comparing the FN and non-FN groups, there is no significant difference in
baseline demographics. Estimated yearly incidences for OCSCC in the Alberta population (all ages) and FN patients are
1.74/100,000 and 1.32/100,000 respectively (p = 0.23). Significant differences are seen in overall survival (OS) (5-year OS
58.1% for non-FN and 33.7% for FN) and for disease-specific survival (DSS) (5-year DSS 67.8% for non-FN and 44.5% for
FN). Multivariate analysis confirmed FN patients have a significant increase risk of death in OS and DSS, with hazard
ratios of 4.20 (p = 0.01) and 4.57 (p = 0.02), respectively.
Conclusions: The overall survival and disease specific survival are significantly lower in FN patients compared to
non-FN patients with OCSCC.
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Oral cavity squamous cell carcinoma (OCSCC) is the
most common head and neck cancer, affecting approxi-
mately 2000 Canadians every year [1]. The most common
risk factors associated with OCSCC are tobacco and alco-
hol use [2]. These factors independently increase the risk* Correspondence: entsurgeonalberta@gmail.com
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unless otherwise stated.of OCSCC, but also have a synergistic effect when used in
combination [3]. Overall, the incidence of OCSCC is de-
creasing, which is thought to be related to decreased
smoking rates. Data from the Canadian Cancer Registry
between 1992 and 2007 demonstrates a decrease in inci-
dence of oral cavity cancer by 2.1% for men and 0.4% for
women [4]. This registry has also shown that survival out-
comes are improving for OCSCC with an 8.1% increase in
survival for men [4]. These trends of decreasing incidencel. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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United States of America [5].
First Nations (FN) people of Canada are defined as
those who are associated with a First Nations band and
are Aboriginal, without being Metis or Inuit. There are
significant health disparities in FN people in Canada
based on determinants of health. The incidence of can-
cer in FN is significantly lower when compared to the
general population, but the cancer-related morbidity and
mortality is significantly higher. The Alberta Health and
Wellness data confirms that between 2000 and 2011, in
Alberta, there has been a much higher cancer-related
mortality in FN groups. The Canadian literature is very
limited, but there is evidence that FN patients do have
lower incidence of OCSCC than the overall population.
In one study, the Ontario FN patients were reported to
have significantly lowered rates of oral cavity cancer
from 1968-1991 [6]. There is no Canadian literature cur-
rently for OCSCC, or any other head and neck cancer,
that compares survival outcomes of FN to the overall
population. Therefore, the objective of this study is to
determine whether there is a difference in epidemiology
and survival outcomes between FN and non-FN patients
with OCSCC.
Methods
Prior to commencement of this study, ethics was ob-
tained from the University of Alberta Health Research
Ethics Board (Pro00016426). Inclusion criteria included
all patients with OCSCC [7], diagnosed and treated in
Alberta between January 1, 1998 to December 31, 2009.
Prospectively collected data from the Alberta Cancer
Registry (ACR) and clinic charts were used to obtain pa-
tient information. The ACR is certified by the North
American Association for Central Cancer Registries and
is responsible for recording and tracking all new diagno-
ses of cancer, their treatments and deaths, through
mandatory reporting enforced by legislation in the prov-
ince of Alberta, Canada [8].
Collected information included demographics (age at
time of diagnosis, gender, smoking and alcohol status,
and FN status), clinical presentation (staging at diagno-
sis), treatment patterns, functional status (ECOG) [9]
and survival outcomes. Smoking status was tabulated
from clinic charts and cancer centre charts. Patients
with 10 pack year history or more were classified as
smokers, given the established prognostic value of this
cutoff point [10]. Patients who had quit smoking for
20 years or longer were given a non-smoking status, in
accordance with previously published literature [11]. FN
status was identified using 2 methods: 1) patients with
postal codes associated with one of the 140 Aboriginal
Affairs and Northern Development Canada listed reserves
and 2) patients with FN status as specified by the AlbertaHealth and Wellness registry file (registered under the
Canadian Federal Indian Act), as described in previous
studies [12-14].
Statistical methods
Survival time was calculated in years from time of
pathologic diagnosis to date last known alive by follow-
up or electronic medical records, or date of death using
a right censoring method. Cause of death was classified
as either disease-specific (DSS) or from other causes for
calculation overall survival (OS), as determined by the
ACR and chart review [15,16].
SPSS version 22.0 was used for all statistical analyses
(SPSS Inc., Chicaco, IL, USA). The Kaplan-Meier algo-
rithm was used to estimate overall and disease specific
survival, employing the Log-rank test to compare strata
[17]. The Cox proportional hazards model [18] was used
to perform a multivariate analysis of factors and covari-
ates, including age, gender, TNM staging, tumor subsite,
treatment, smoking status and FN status. Pearson’s chi-
square and the Mann Whitney U test used to calculate dif-
ferences between groups where appropriate. Standardized
incidence ratios (SIRs) were calculated as previously de-
scribed [19], using census data from Alberta Health and
Wellness. Statistical significance was defined as p < 0.05.
Ethics approval
Prior to commencement of this study, ethics approval
was obtained from the University of Alberta Health
Research Ethics Board.
Results
A total of 583 patients with OCSCC were included in this
study. Of these, 19 were identified as being FN, leaving
564 non-FN patients. When comparing patient demo-
graphics, none of the baseline parameters were found
to be significantly different between the groups (Table 1).
The age at diagnosis and gender distribution of non-FN
and FN was very similar (61.8 years vs. 60.7 years; p = 0.65
and 56.7% males vs. 36.8% males; p = 0.08, accordingly).
The two groups had similar distribution of tumor subsite
as well at TNM staging at diagnosis. Rates of tobacco and
alcohol use were similar in the groups. Finally, the ECOG
scores and treatment modalities employed were not found
to be significantly different between FN and non-FN
patients.
The estimated yearly incidence was 1.74/100,000 for
all OCSCC patients in Alberta and 1.32/100,000 for FN
patients. The mean incidence from 1998–2009 was not
significantly different (p = 0.23) between FN and non-FN
patients.
FN patients diagnosed with OCSCC had significantly
decreased survival compared to non-FN patients (Figures 1
and 2). At 5 years, FN had an OS of 33.7% compared to
Table 1 Characteristics of 583 patients with oral cavity squamous cell carcinoma
Characteristics All (n = 583) Non-FN (n = 564) FN (n = 19) pa
Age (mean, SD) 61.7 61.8 60.7 0.65
Gender (%M) 56.1 56.7 36.8 0.08
Tumor Subsite (%) 0.95
Tongue 48.0 48.0 47.3
Gum 10.2 10.3 10.5
Mouth 17.3 17.4 15.7
Floor of Mouth 21.9 21.8 26.3
Palate 1.5 1.6 0
Lips 0.9 0.9 0
TNM Stage (% stage early, I/II) 59.5 59.5 57.9 0.88
Tobacco (%) 67.1 66.8 76.5 0.29
Alcohol use (%) 64.8 64.5 80.0 0.42
ECOG (%) 0.73
0 56.9 56.9 58.9
1 31.6 31.4 35.2
2 7.5 7.6 5.9
3+ 4.0 4.1 0
Treatmentb 0.12
S + RT/CRT 32.6 37.6 47.4
CRT 1.9 2.0 0
S 52.1 52.6 36.8
RT 7.9 7.8 10.5
SD, standard deviation; %M, percent males; S, surgery; RT, radiation therapy; CRT, chemoradiation therapy.
ap-value for Mann–Whitney test comparing FN vs non-FN grouping variables, with significance denoted for values <0.05.
b43 patients did not receive treatment (2 FN and 41 non-FN).
Figure 1 Title: Overall survival in FN vs non-FN patients. Legend:
At 5 years, First Nations (FN) had an overall survival (OS) of 33.7%
compared to 58.1% for non-FN (p < 0.05).
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also decreased for FN patients, with a 5-year rate of 44.5%
compared to 67.8% for non-FN (p < 0.05).
Upon multivariable analysis (Table 2), FN status pre-
dicted significantly worse survival. Hazards ratio for OS
was 4.2 (p = 0.01) and for DSS 4.57 (p = 0.02). The other
covariates were not significant predictors of survival.
Discussion
The cancer-related mortality in FN people of Canada is
significantly higher than in the general population. In
this study, FN people with OCSCC in Alberta were
found to have significantly worse survival outcomes than
non-FN people. The findings are confirmed with both
Log-rank testing of 5-year survival rates as well as multi-
variate analysis. This is the first Canadian study to con-
firm this relationship, and the results are consistent with
published data on indigenous American populations in
the United States. Several recent American studies have
investigated head and neck cancer in Aboriginal people
using the Surveillance, Epidemiology, and End Results
(SEER) Program Research Data [20,21]. Dwojak et al., in
2012, found that there was no significant difference in
Figure 2 Title: Disease specific survival in FN vs non-FN patients.
Legend: At 5 years, First Nations (FN) had a disease-specific survival
(DSS) of 44.5% compared to 67.8% for non-FN (p < 0.05).
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demographic characteristics there was a decreased sur-
vival in American Indians/Alaska Natives (AI/AN), with
a hazard ratio of 1.3 (p = 0.05).
We did not find any significant difference in incidence
of OCSCC between FN and non-FN people of Alberta.
This is in disagreement with the sole published Canadian
study, which attempted to analyze oral cavity cancer inci-
dence amongst FN people by Marrett and Chaudhry 6.
The incidence of oral cavity cancer in status Indians in
Ontario was found to be significantly lower than non-status
Indians with ratio of incidence of 0.98 (95% CI 0.61-1.51) in
females and 0.65 (95% CI 0.42-0.97) in males. Further
descriptions are found when looking at American data.
Reichman et al., in 2008, showed that there was a wideTable 2 Multivariate analysis
Overall survival
Covariate Hazard ratio (95% CI)
Age 0.99 (0.97-1.01)
Female gender 0.71 (0.42-1.20)
First Nations (vs Non) 4.20 (1.43-12.27
Smoking (vs non-smoker) 1.29 (0.65-2.58)
Alcohol use 0.65 (0.31-1.36)
Treatment
S + CRT (ref) 1




TNM stage advanced 1.34 (0.58-3.10)
S, surgery; RT, radiation therapy; CRT, chemoradiation therapy.variance of incidence in head and neck cancers amongst
AI/AN based on location and specific site of involvement.
When examining the oral cavity, it is described that the ra-
tio of AI/AN to non-hispanic white patients was 0.55,
0.76, and 0.70, for tongue, gingiva, and floor of mouth re-
spectively [21].
These discrepancies lead to the concern of FN report-
ing amongst health data collection as described by
Hoopes et al., in 2012 [22]. When there is misrepresen-
tation among relatively small populations, such as FN
people, it can significantly affect population-based esti-
mates of incidence and survival. Previous Alberta studies
focusing on FN rates of disease have used the Alberta
Health Services FN Status Registry alone to identify FN
patients [12,14,23]. Our study is the first to use a more
inclusive definition by identifying FN patients through
FN reserve postal code correlation.
We were able to quantify tobacco and alcohol use
amongst patients, although this data is somewhat subject-
ive. Smoking rates in FN people are higher and trending
down at a slower rate than amongst the general Canadian
population [24,25], but our study did not show any signifi-
cant difference in smoking rates between the two groups.
We believe this is due to very high rates of smoking in
both cancer groups when compared to the overall popula-
tion. We did not include histological grade in our analysis,
as historically this has not been proven to be a strong
predictor of survival [26,27]. This may be considered a
limitation to our study.
The significantly decreased survival outcomes of FN
patients with OCSCC in Alberta is concerning and war-
rants further investigation. A number of possibilities may
explain differences between FN and non-FN patients
shown here. Access to healthcare, especially in FN patients
in remote regions of Alberta, may delay diagnosis andDisease specific survival
p value Hazard ratio (95% CI) p value
0.26 0.99 (097–1.01) 0.16
0.20 0.61 (0.34-1.11) 0.11
0.01 4.57 (1.31-15.92) 0.02
0.47 1.41 (0.65-3.10) 0.39
0.25 0.63 (0.27-1.45) 0.27
1
0.51 0.76 (0.21-2.71) 0.67
0.39 1.94 (0.20-19.04) 0.57
0.02 8.43 (1.89-37.63) 0.01
0.57 1.42 (0.65-3.11) 0.52
0.49 0.98 (0.39-2.47) 0.97
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could be responsible for lower survival outcomes in FN
patients but research in this area is currently lacking.
Conclusion
The incidence of OCSCC is similar for FN and overall
populations in Alberta. However, both the OS and DSS
are significantly lower in FN compared to non-FN patients
with OCSCC. This result has been shown to be independ-
ent of variables such as risk factors, stage at presentation,
and treatment modalities.
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